SCHEMBL20143373

SCHEMBL20143373

O=C(Nc1ccccc1)C(=O)OCc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.62
POLB P06746 2/20 0.55
KMT2A Q03164 3/20 0.55
SLC6A2 P23975 1/20 0.55
SLC6A3 Q01959 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
RAB9A P51151 2/20 0.54
GAA P10253 1/20 0.54
MGLL Q99685 1/20 0.53
HTT P42858 1/20 0.51
SGMS2 Q8NHU3 1/20 0.50
MAPK1 P28482 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
EPHX2 P34913 1/20 0.50
LMNA P02545 1/20 0.50
MEN1 O00255 1/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20029254 0.90 ALDH1A1 (0.60) ALDH1A1POLBKMT2ASLC6A2SLC6A3
SCHEMBL9363349 0.89 POLB (0.73) ALDH1A1POLBKMT2ASLC6A2SLC6A3
SCHEMBL11057368 0.89 ALDH1A1 (0.59) ALDH1A1POLBKMT2ASLC6A2SLC6A3
SCHEMBL20029258 0.85 MGLL (0.56) ALDH1A1POLBKMT2ARAB9AGAA
SCHEMBL20023001 0.83 ALDH1A1 (0.56) ALDH1A1POLBKMT2ATDP1RAB9A
SCHEMBL20029246 0.83 ALDH1A1 (0.60) ALDH1A1KMT2ARAB9AGAAEPHX2
SCHEMBL20029049 0.82 MGLL (0.59) ALDH1A1KMT2ARAB9AGAAMGLL
Benzyl Phenylcarbamate SCHEMBL1222943 0.81 POLB (0.78) ALDH1A1POLBRAB9AMGLLLMNA
SCHEMBL27144 0.80 ALDH1A1 (0.68) ALDH1A1KMT2ASLC6A2SLC6A3TDP1
SCHEMBL23994825 0.80 TDP1 (0.55) ALDH1A1KMT2ASLC6A2SLC6A3TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11660280-B2 Treatment of drug resistant gliomas OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 2023-05-30 US disclosed
US-11084852-B2 Ubiquitin interacting motif peptides as therapeutics OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 2021-08-10 US disclosed
US-20200215015-A1 TREATMENT OF DRUG RESISTANT GLIOMAS OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 2020-07-09 US disclosed
US-10398659-B2 Adjuvant chemotherapy for anaplastic gliomas OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 2019-09-03 US disclosed
WO-2019060152-A1 TREATMENT OF DRUG RESISTANT GLIOMAS OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 2019-03-28 WO disclosed
US-9968569-B2 Adjuvant chemotherapy for anaplastic gliomas OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 2018-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11084852-B2 Ubiquitin interacting motif peptides as therapeutics UBXN1, UBQLN1, UFM1 ALDH1A1 4400/4885POLB 2216/4885KMT2A 2691/4885
US-20200215015-A1 TREATMENT OF DRUG RESISTANT GLIOMAS MGMT, NES, DCX ALDH1A1 1343/4885POLB 1018/4885KMT2A 1384/4885
US-11660280-B2 Treatment of drug resistant gliomas MGMT, NES, DCX ALDH1A1 1343/4885POLB 1018/4885KMT2A 1384/4885
US-10398659-B2 Adjuvant chemotherapy for anaplastic gliomas TRIB2, NES, DCX ALDH1A1 271/4885POLB 2333/4885KMT2A 1182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.